Filtered By:
Condition: Atrial Fibrillation
Therapy: Dialysis

This page shows you your search results in order of date. This is page number 7.

Order by Relevance | Date

Total 241 results found since Jan 2013.

A systematic review of the efficacy and safety of anticoagulants in advanced chronic kidney disease
CONCLUSION: Further studies are still required, some ongoing, in patients with advanced CKD (CrCl < 30 ml/min) to identify the safest and most effective treatment options for VTE and AF.PMID:36006608 | DOI:10.1007/s40620-022-01413-x
Source: Journal of Nephrology - August 25, 2022 Category: Urology & Nephrology Authors: Kathrine Parker John Hartemink Ananya Saha Roshni Mitra Penny Lewis Albert Power Satarupa Choudhuri Sandip Mitra Jecko Thachil Source Type: research

Impact of preoperative atrial fibrillation on in-hospital outcomes of coronary artery bypass grafting
The objective of our study was to assess if preoperative AF in patients undergoing coronary artery bypass grafting is a predictor of operative mortality, postoperative stroke and need for postoperative dialysis by interrogating a large registry database.
Source: Seminars in Thoracic and Cardiovascular Surgery - July 13, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Daniel Paul Fudulu, Arnaldo Dimagli, Shubhra Sinha, James Ackah, Pradeep Narayan, Jeremy Chan, Marco Gemelli, Tim Dong, Umberto Benedetto, Gianni Davide Angelini Tags: ADULT – Original Submission Source Type: research

Po-701-04 outcomes of left atrial appendage closure in patients with atrial fibrillation and end-stage renal disease on dialysis
Oral anticoagulation (OAC) therapy is the mainstay of treatment for stroke-risk reduction in patients with atrial fibrillation (AF). However, OAC use in patients with end-stage renal disease (ESRD) on dialysis is associated with a significantly increased risk of bleeding and an uncertain benefit in stroke reduction. In these patients, left atrial appendage closure (LAAC) could be alternative.
Source: Heart Rhythm - April 29, 2022 Category: Cardiology Authors: Jorge Romero, Juan C. Diaz, Sutopa Purkayastha, Jorge Marin, Julian M. Aristizabal, Daniel Rodriguez, Isabella Alviz, Mauricio Duque, Mohamed Gabr, Maria Gamero, Jose Matias, Marta Lorente-Ros, Luis Ernesto Cerna, Dhanunjaya R. Lakkireddy, Rishi Charate, Source Type: research

Duration and clinical outcome of dual antiplatelet therapy after percutaneous coronary intervention: a retrospective cohort study using a medical information database from Japanese hospitals
In conclusion, early DAPT discontinuation is more likely in patients at high bleeding risk, but may influence the occurrence of ischemic events in these patients. Determination of DAPT duration should take into account potential ischemic risk, even in patients at high bleeding risk.
Source: Cardiovascular Intervention and Therapeutics - February 9, 2022 Category: Cardiology Source Type: research

Warfarin Use, Stroke, and Bleeding Risk among Pre-Existing Atrial Fibrillation US Veterans Transitioning to Dialysis
In this study, we validated risk scores for stroke and bleeding in this population and assessed risk of stroke and bleeding among warfarin users compared to nonusers.Methods: We utilized a cohort of 28,620 pre-dialysis US veterans transitioning to hemodialysis between October 2007 and March 2015. Incident rates for the risks of stroke and bleeding were ascertained based upon CHA2DS2-VASc or HAS-BLED scores, respectively. A propensity score-based competing risk analysis was used to assess risk of stroke and bleeding.Findings: The mean age of our cohort was 77 ± 9 years, and the median CHA2DS2-VASc and HAS-BLED scores were ...
Source: Nephron - February 4, 2022 Category: Urology & Nephrology Source Type: research

Can I use DOAC in a patient with renal disease?
Case A 76-year-old man is diagnosed with non-valvular atrial fibrillation. His comorbid conditions are hypertension, diabetes complicated by neuropathy, and chronic kidney disease stage 3. His current medications include metformin, lisinopril, gabapentin, and aspirin. His most recent laboratories showed a creatinine 1.8, creatinine clearance (CrCl) 35 mL/min, hemoglobin 11g/dL, and international normalized ratio 1.0. His congestive heart failure, hypertension, age, diabetes, stroke, vascular disease, and sex (CHADSVASc) score is 4. Which medication should we use to prevent stroke in this patient?  Brief overview of the is...
Source: The Hospitalist - February 3, 2022 Category: Hospital Management Authors: Ronda Whitaker Tags: Renal & Genitourinary Source Type: research

Comparison of Clevidipine and Nicardipine for Acute Blood Pressure Reduction in Hemorrhagic Stroke
ConclusionsIn patients with hemorrhagic stroke, nicardipine appeared to have similar efficacy as clevidipine in SBP reduction, with a more likely reduction of rebound hypertension and drug cost. This retrospective study was underpowered, which may limit these implications. Further prospective studies are warranted to confirm these results.
Source: Neurocritical Care - December 13, 2021 Category: Neurology Source Type: research

Medical costs for managing chronic kidney disease and related complications in patients with chronic kidney disease and type 2 diabetes
CONCLUSIONS: Management of CKD and its complications incurs high medical costs for patients with CKD and T2D. Results from this study can be used to quantify the economic profile of emerging treatments and inform decision-making.PMID:34878754 | DOI:10.37765/ajmc.2021.88807
Source: The American Journal of Managed Care - December 8, 2021 Category: Health Management Authors: Keith A Betts Jinlin Song Elizabeth Faust Karen Yang Yuxian Du Sheldon X Kong Rakesh Singh Source Type: research

Anticoagulation in special patient populations with atrial fibrillation
Herz. 2021 Jul 5. doi: 10.1007/s00059-021-05042-1. Online ahead of print.ABSTRACTAnticoagulation in patients with atrial fibrillation (AF) should be guided by considerations of the risk of thromboembolism, stroke, and bleeding as well as the patient's preference. Well-recognized scores have been developed to help the clinician in daily risk assessment, but there are several special patient populations for whom scores are not developed or validated. Furthermore, these patients were not adequately represented in the pivotal randomized trials for non-vitamin K antagonist oral anticoagulants (NOACs). In patients with cancer, t...
Source: Herz - July 5, 2021 Category: Cardiology Authors: Laura Ueberham Gerhard Hindricks Source Type: research